Bell Potter slaps buy rating on this profitable, dividend-paying ASX cannabis share

This cannabis share is smoking the market on Monday…

The Cronos Australia Ltd (ASX: CAU) share price was a strong performer on Monday.

The medicinal cannabis company's shares ended the day 15% higher at 55 cents.

At one stage, the Cronos Australia share price even reached a record high of 58 cents.

two men in formal business clothing closely inspect a bud from a cannabis crop.

Image source: Getty Images

Why did the Cronos Australia share price fire up?

Investors have been scrambling to buy the company's shares over the last two trading sessions thanks to a bullish broker note out of Bell Potter.

According to the note, the broker has initiated coverage on the company with a buy rating and 60 cents price target.

Based on the current Cronos Australia share price, this implies further potential upside of 9.1% for investors.

What did the broker say?

Bell Potter likes the company due to its leadership position in medicinal cannabis distribution. It explained:

Cronos Australia is a medicinal cannabis company that is the market leader in distribution to pharmacies and provides patient consulting services through its clinic business. The key driver for the impressive growth in the past 24 months has been the CanView platform which provides the widest range of medicinal cannabis products compared to competitors (Anspec, Health House).

The current system provides access to patients, doctors and pharmacists. The transition to CanView 2.0 streamlines the consultation and prescription process.

In addition, the broker highlights that Cronos Australia is a profitable, dividend-paying cannabis share. The only one of its kind in Australia. Furthermore, it feels its valuation is fair and its growth outlook is strong. The broker concludes:

We initiate coverage on Cronos with a Buy recommendation. We expect the momentum observed in FY22 to continue into FY23 and translate into strong revenue and earnings growth. Cronos is currently the only profitable dividend paying medicinal cannabis company on the ASX and the valuation does not appear demanding relative to the expected growth.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Shot of a young businesswoman looking stressed out while working in an office.
Broker Notes

6 ASX stocks receiving analyst downgrades this week

Brokers reduced their ratings on NextDC, Ampol, Regis Resources, and other stocks this week. 

Read more »

Facebook thumbs up symbol surrounded by boxes with the word 'Like'.
Broker Notes

6 ASX stocks upgraded by leading brokers this week

Brokers have raised their ratings on Pro Medicus, South32, New Hope, and others. 

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

6 ASX shares experts are backing amid the market downturn

Brokers maintained a positive view on Qantas, NAB, Maas Group, BHP, and other shares.

Read more »

Two work colleagues looking at a laptop and discussing something.
Broker Notes

Should you buy Hub24, Northern Star, and Transurban shares?

Morgans has given its verdict on these shares. Is it time to buy? Let's find out.

Read more »

Man and woman holding a tablet and clipboard while looking at the backside of server racks in a data centre.
Broker Notes

Buy, hold, sell: Sigma, Cliunvel, and NextDC shares

Let's see how analysts rate these shares this week.

Read more »

AI microprocessor on motherboard computer circuit.
Broker Notes

Xero or hero? UBS predicts the latter with huge upside for the accounting stock

AI is not all doom and gloom for this accounting software provider.

Read more »

Diagram of black male figure with question marks on top and arrows on wooden blocks on each side.
Broker Notes

Buy, hold, sell: JB Hi-Fi, Xero, Northern Star Resources shares

Experts reveal their ratings on 3 ASX shares in the retail, gold mining, and tech segments.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

Buy, hold, sell: Ramelius Resources, Harvey Norman, Santos shares

Let's check out some new ratings on ASX shares today.

Read more »